Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of oral GB2064 in participants with myelofibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• GB2064

Snippet

Sponsor: Galecto Biotech AB | Conditions: Myelofibrosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING